Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP

Experimental Neurology

Volumn 189, Issue 2, 2004, Pages 393-403

  Betarbet, Ranjita ^a,b   Greenamyre, J Timothy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

D1 dopamine receptor; D2 dopamine receptor; Enkephalin; MPTP; Parkinson's disease; Substance P

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; ENKEPHALIN; NEUROPEPTIDE; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; FEMALE; GLOBUS PALLIDUS; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; DOWN-REGULATION; ENKEPHALINS; FEMALE; FUNCTIONAL LATERALITY; GLOBUS PALLIDUS; MACACA MULATTA; NEOSTRIATUM; NEUROPEPTIDES; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SUBSTANCE P; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 4544273531     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.05.041     Document Type: Article

References (85)

1. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat. New Biol. 245:1973;150-151
2. Aizman O., Brismar H., Uhlen P., Zettergren E., Levey A.I., Forssberg H., Greengard P., Aperia A. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3:2000;226-230
3. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375
4. Alexander G.M., Brainard D.L., Gordon S.W., Hichens M., Grothusen J.R., Schwartzman R.J. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates. Brain Res. 547:1991;181-189
5. Algeri S., Brunello N., Calderini G., Consolazione A. Effect of enkephalins on catecholamine metabolism in rat CNS. Adv. Biochem. Psychopharmacol. 18:1978;199-210
6. Asselin M.C., Soghomonian J.J., Cote P.Y., Parent A. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. NeuroReport. 5:1994;2137-2140
7. Augood S.J., Emson P.C., Mitchell I.J., Boyce S., Clarke C.E., Crossman A.R. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Res. Mol. Brain Res. 6:1989;85-92
8. Beckstead R.M. The thalamostriatal projection in the cat. J. Comp. Neurol. 223:1984;313-346
9. Betarbet R., Porter R.H.P., Greenamyre J.T. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J. Neurochem. 74:2000;1166-1174
10. Betarbet R., Poisik O., Sherer T.B., Greenamyre J.T. Differential expression and ser897 phosphorylation of striatal N-methyl-D-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp. Neurol. 187:2004;76-85
11. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Neurobiol. Dis. 8:2001;343-350
12. Breese G.R., Duncan G.E., Napier T.C., Bondy S.C., Iorio L.C., Mueller R.A. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonists binding. J. Pharmacol. Exp. Ther. 240:1987;167-176
13. Costa E., Carenzi A., Guidotti A. Narcotic Analgesics and the Regulation of Neuronal Catecholamine Stores. 1973;Pergamon Press, London
14. Crossman A.R. Neural mechanisms in disorders of movement. Comp. Biochem. Physiol., A. 93:1989;141-149
15. De Ceballos M.L., Lopez-Lozano J.J. Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies. Peptides. 20:1999;249-257
16. de Ceballos M.L., Fernandez A., Jenner P., Marsden C.D. Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients. Neurosci. Lett. 160:1993;163-166
17. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285
18. Diamond B.I., Borison R.L. Enkephalins and nigrostriatal function. Neurology. 28:1978;1085-1088
19. Divac I., Fonnum F., Storm-Mathisen J. High affinity uptake of glutamate in terminals of corticostriatal axons. Nature. 266:1977;377-378
20. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg A., Lee E.J., Huang S.P., et al. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12564-12568
21. Fernandez A., de Ceballos M.L., Rose S., Jenner P., Marsden C.D. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain. 119:1996;823-830
22. Frohna P.A., Rothblat D.S., Joyce J.N., Schneider J.S. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Synapse. 19:1995;46-55
23. 2 receptor agonists. Eur. J. Pharmacol. 178:1990;115-120
24. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends. Neurosci. 15:1992;133-139
25. Gerfen C.R., Wilson C.J. The basal ganglia. Swanson L.W., Bjorklund A., Hokfelt T. Handbook of Chemical Neuroanatomy. 1996;Elsevier Science, San Diego
26. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432
27. Gerfen C.R., McGinty J.F., Young W.S. III Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031
28. Gerlach M., Reiderer P. The pathophysiological basis of Parkinson's disease. Szelenyi I. Inhibitors of Monoamine Oxidase B. 1993;25-50 Birkhauser, Boston
29. 2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse. 14:1993;184-194
30. Goto S., Hirano A., Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology. 40:1990;1051-1056
31. Grafe M.R., Forno L.S., Eng L.F. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J. Neuropathol. Exp. Neurol. 44:1985;47-59
32. Graham W.C., Clarke C.E., Boyce S., Sambrook M.A., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 514:1990;103-110
33. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transm.: Gen. Sect. 91:1993;255-269
34. Gudehithlu K.P., Duchemin A.M., Tejwani G.A., Neff N.H., Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin increase in mouse striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. J. Neurochem. 56:1991;1043-1048
35. Haber S.N., Watson S.J. The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal forebrain. Neuroscience. 14:1985;1011-1024
36. Hokfelt T., Elde R., Johansson O. The distribution of enkephalin-immunoreactive cell bodies in the rat central nervous system. Neurosci. Lett. 5:1977;25-31
37. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-964
38. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34
39. Kemp J.M., Powell T.P. The structure of the caudate nucleus of the cat: light and electron microscopy. Philos. Trans. R Soc. Lond., B Biol. Sci. 262:1971;383-401
40. Klockgether T., Turski L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci. 12:1989;285-286
41. Kozlowski M.R., Marshall J.F. Plasticity of [14C]2-deoxy-D-glucose incorporation into neostriatum and related structures in response to dopamine neuron damage and apomorphine replacement. Brain Res. 197:1980;167-183
42. Krasnova I.N., Bychkov E.R., Lioudyno V.I., Zubareva O.E., Dambinova S.A. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Neuroscience. 95:2000;113-117
43. Lavoie B., Parent A., Bedard P.J. Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys. Can. J. Neurol. Sci. 18:1991;373-375
44. Levey A.I., Hersch S.M., Rye D.B., Sunahara R.K., Niznik H.B., Kitt C.A., Price D.L., Maggio R., Brann M.R., Ciliax B.J., et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8861-8865
45. Levy R., Vila M., Herrero M.T., Faucheux B., Agid Y., Hirsch E.C. Striatal expression of substance P and methionine-enkephalin in genes in patients with Parkinson's disease. Neurosci. Lett. 199:1995;220-224
46. Maneuf Y.P., Mitchell I.J., Crossman A.R., Brotchie J.M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125:1994;65-71
47. Martin L.J., Hadfield M.G., Dellovade T.L., Price D.L. The striatal mosaic in primates: patterns of neuropeptide immunoreactivity differentiate the ventral striatum from the dorsal striatum. Neuroscience. 43:1991;397-417
48. Martin L.J., Blackstone C.D., Huganir R.L., Price D.L. The striatal mosaic in primates: striosomes and matrix are differentially enriched in ionotropic glutamate receptor subunits. J. Neurosci. 13:1993;782-792
49. McGeorge A.J., Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537
50. Mileson B.E., Lewis M.H., Mailman R.B. Dopamine receptor supersensitivity occurring without receptor up-regulation. Brain Res. 561:1991;1-10
51. Moore R.Y., Bhatnagar R.K., Heller A. Anatomical and chemical studies of a nigro-neostriatal projection in the cat. Brain Res. 30:1971;119-135
52. Morissette M., Goulet M., Calon F., Falardeau P., Blanchet P.J., Bedard P.J., Di Paolo T. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol. Pharmacol. 50:1996;1073-1079
53. Nisbet A.P., Foster O.J., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 66:1995;361-376
54. Niznik H.B., Van Tol H.H. Dopamine receptor genes: new tools for molecular psychiatry. J. Psychiatry Neurosci. 17:1992;158-180
55. Parent A. Comparative Neurobiology of the Basal Ganglia. 1986;Wiley-Interscience, New Jersey
56. Parent A., Mackey A., De Bellefeuille L. The subcortical afferents to caudate nucleus and putamen in primate: a fluorescence retrograde double labeling study. Neuroscience. 10:1983;1137-1150
57. Perez-Otano I., Herrero M.T., Luquin M.R., Obeso J.A., Del Rio J. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset. Brain Res. 585:1992;156-160
58. Pierot L., Desnos C., Blin J., Raisman R., Scherman D., Javoy-Agid F., Ruberg M., Agid Y. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J. Neurol. Sci. 86:1988;291-306
59. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with Lewy bodies. Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 122:1999;1449-1468
60. Pimoule C., Schoemaker H., Reynolds G.P., Langer S.Z. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur. J. Pharmacol. 114:1985;235-237
61. Pope-Coleman A., Tinker J.P., Schneider J.S. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse. 36:2000;120-128
62. Przedborski S., Jackson-Lewis V., Popilskis S., Kostic V., Levivier M., Fahn S., Cadet J.L. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirurgia. 37:1991;377-382
63. Raisman R., Cash R., Ruberg M., Javoy-Agid F., Agid Y. Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur. J. Pharmacol. 113:1985;467-468
64. Reid M.S., Herrera-Marschitz M., Kehr J., Ungerstedt U. Striatal dopamine and glutamate release: effects of intranigral injections of substance P. Acta Physiol. Scand. 140:1990;527-537
65. Rinne J.O., Rinne J.K., Laakso K., Lonnberg P., Rinne U.K. Dopamine D-1 receptors in the parkinsonian brain. Brain Res. 359:1985;306-310
66. Rioux L., Frohna P.A., Joyce J.N., Schneider J.S. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov. Disord. 12:1997;148-158
67. Roeling T.A., Docter G.J., Voorn P., Melchers B.P., Wolters E.C., Groenewegen H.J. Effects of unilateral 6-hydroxydopamine lesions on neuropeptide immunoreactivity in the basal ganglia of the common marmoset, Callithrix jacchus, a quantitative immunohistochemical analysis. J. Chem. Neuroanat. 9:1995;155-164
68. Royce G.J., Mourey R.J. Efferent connections of the centromedian and parafascicular thalamic nuclei: an autoradiographic investigation in the cat. J. Comp. Neurol. 235:1985;277-300
69. Schroeder J.A., Schneider J.S. Striatal enkephalin gene expression does not reflect parkinsonian signs. NeuroReport. 11:2000;1799-1802
70. Sibley D.R., Monsma F.J. Jr. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:1992;61-69
71. Song D.D., Haber S.N. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J. Neurosci. 20:2000;5102-5114
72. Tang F.I., Chiu T.H., Wang Y. Electrochemical studies of the effects of substance P on dopamine terminals in the rat striatum. Exp. Neurol. 152:1998;41-49
73. Tanji H., Araki T., Nagasawa H., Itoyama Y. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. Brain Res. 824:1999;224-231
74. Taquet H., Nomoto M., Rose S., Jenner P., Javoy-Agid F., Mauborgne A., Benoliel J.J., Marsden C.D., Legrand J.C., Agid Y., et al. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,- tetrahydropyridine treatment. Neuropeptides. 12:1988;105-110
75. Taylor M.D., de Ceballos M.L., Rose S., Chong P.N., Jenner P., Marsden C.D. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 3:1991;99-108
76. Tenovuo O., Rinne U.K., Viljanen M.K. Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res. 303:1984;113-116
77. Walczak S.A., Wilkening D., Makman M.H. Interaction of morphine, etorphine and enkephalins with dopamine-stimulated adenylate cyclase of monkey amygdala. Brain Res. 160:1979;105-116
78. Waters C.M., Peck R., Rossor M., Reynolds G.P., Hunt S.P. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience. 25:1988;419-438
79. Wichmann T., Bergman H., DeLong M.R. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J. Neurophysiol. 72:1994;521-530
80. Wooten G.F. Neurochemistry and neuropharmacology of Parkinson's disease. Watts R.L., Koller R.C. Movement Disorders: Neurologic Principles and Practice. 1997;153-160 McGraw-Hill, New York
81. Wooten G.F., Collins R.C. Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions. Brain Res. 263:1983;267-275
82. Young A.B., Bromberg M.B., Penney J.B. Jr. Decreased glutamate uptake in subcortical areas deafferented by sensorimotor cortical ablation in the cat. J. Neurosci. 1:1981;241-249
83. Yung K.K., Bolam J.P., Smith A.D., Hersch S.M., Ciliax B.J., Levey A.I. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience. 65:1995;709-730
84. Zech M., Bogerts B. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. Acta Neuropathol. 68:1985;32-38
85. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41:1984;856-861